Carpenter D, Ting M. “The Political Logic of Regulatory Error” . Nature Reviews – Drug Discovery . 2005;4(10):819-823.

Carpenter D, Fendrick MA. “Accelerating Approval Times for New Drugs in the U.S”. The Regulatory Affairs Journal – Pharma. 2004;15(6):411-417.

Carpenter D, Fendrick MA, Chernew M, Smith D. “Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter?” . Health Affairs – Web Exclusive. 2004;W3- 618-624.

Carpenter D, Esterling K, Lazer D. “Friends Brokers and Transitivity: Who Talks with Whom in Washington Lobbying?” . Journal of Politics . 2004;66(1):224-246.

Carpenter D. “Gatekeeping and the FDA’s Role in Human Subjects Protection” . Virtual Mentor [American Medical Association] . 2004;6.

Carpenter D. “The Political Economy of FDA Drug Approval: Processing Politics and Implications for Policy” . Health Affairs. 2004;23(1):52-63.

Carpenter D, Lewis D. “Political Learning from Rare Events: Poisson Inference Fiscal Constraints and the Lifetime of Bureaus” . Political Analysis. 2004;12(3):201-232.

Carpenter D. “Protection without Capture: Product Approval by a Politically Responsive Learning Regulator”. American Political Science Review . 2004;98(4):613-631.

Carpenter D. “Staff Resources Speed FDA Drug Review” . Journal of Health Policy Politics and Law. 2004;29(3):431-442.

Carpenter D, Whittington K. “Executive Power in American Institutional Development” . Perspectives on Politics. 2003;1(3):495-513.

Carpenter D, Cram P, Inadomi J, Vijay S, Fendrick MA. “The Impact of a Celebrity Promotional Campaign on the Use of Colon Cancer Screening: The Case of Katie Couric” . Archives of Internal Medicine . 2003;63:1601-1605.

Carpenter D, Lazer D, Esterling K. “Information and Contact-Making in Policy Networks: A Model with Evidence from the U.S. Health Policy Domain” . Rationality and Society . 2003;15(4):411-440.

Carpenter D. “The Multiple and Material Legacies of Stephen Skowronek” . Social Science History . 2003;27(3):465- 474.

Carpenter D. “Why Do Bureaucrats Delay? Lessons from a Stochastic Optimal Stopping Model of Product Approval” forthcoming . In: Meier K, Krause G ; 2003.

Carpenter D. “Why Do Bureaucrats Delay? Lessons from a Stochastic Optimal Stopping Model of Product Approval” forthcoming. In: Meier K, Krause G Scientific Approaches to Bureaucratic Politics. Ann Arbor: University of Michigan Press; 2003.

Carpenter D. “Groups the Media Agency Waiting Costs and FDA Drug Approval”. American Journal of Political Science. 2002;46(2):490-505.

Carpenter D. The Forging of Bureaucratic Autonomy: Networks, Reputations and Policy Innovation in Executive Agencies, 1862- 1928.; 2001. Website

Carpenter D. “The Political Foundations of Bureaucratic Autonomy: A Reply to Kernell” . Studies in American Political Development . 2001;15(1):113-122.

Carpenter D. Robert Wood Johnson Foundation Scholars in Health Policy Working Paper #21. In: 2000 Midwest Political Science Association. ; 2000.

Carpenter D. “State Building through Reputation Building: Policy Innovation and Coalitions of Esteem at the Post Office 1883-1912” . Studies in American Political Development . 2000;14(2):121-55.